shp53 pLKO.1 puro Citations (44)
Originally described in: Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression.Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, McAllister SS, Jacks T, Weinberg RA Cell. 2008 Jul 11. 134(1):62-73. PubMed Journal
Articles Citing shp53 pLKO.1 puro
| Articles |
|---|
| Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors. Tripathi R, Samadder T, Gupta S, Surolia A, Shaha C. Mol Cancer Ther. 2011 Feb;10(2):255-68. doi: 10.1158/1535-7163.MCT-10-0606. Epub 2011 Jan 7. PubMed |
| Loss of DLK expression in WI-38 human diploid fibroblasts induces a senescent-like proliferation arrest. Daviau A, Couture JP, Blouin R. Biochem Biophys Res Commun. 2011 Sep 23;413(2):282-7. doi: 10.1016/j.bbrc.2011.08.086. Epub 2011 Aug 27. PubMed |
| Live-cell imaging visualizes frequent mitotic skipping during senescence-like growth arrest in mammary carcinoma cells exposed to ionizing radiation. Suzuki M, Yamauchi M, Oka Y, Suzuki K, Yamashita S. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e241-50. doi: 10.1016/j.ijrobp.2011.12.003. Epub 2012 Feb 24. PubMed |
| p53-mediated heterochromatin reorganization regulates its cell fate decisions. Mungamuri SK, Benson EK, Wang S, Gu W, Lee SW, Aaronson SA. Nat Struct Mol Biol. 2012 Apr 1;19(5):478-84, S1. doi: 10.1038/nsmb.2271. PubMed |
| DNA damage causes TP53-dependent coupling of self-renewal and senescence pathways in embryonal carcinoma cells. Jackson TR, Salmina K, Huna A, Inashkina I, Jankevics E, Riekstina U, Kalnina Z, Ivanov A, Townsend PA, Cragg MS, Erenpreisa J. Cell Cycle. 2013 Feb 1;12(3):430-41. doi: 10.4161/cc.23285. Epub 2012 Feb 1. PubMed |
Inhibition of BET bromodomain targets genetically diverse glioblastoma.
Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, Thompson RC, Muller S, Knapp S, Wang J.
Clin Cancer Res. 2013 Apr 1;19(7):1748-59. doi: 10.1158/1078-0432.CCR-12-3066. Epub 2013 Feb 12.
PubMed
Associated Plasmids |
| Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. Bhatt S, Ashlock BM, Toomey NL, Diaz LA, Mesri EA, Lossos IS, Ramos JC. J Clin Invest. 2013 Jun;123(6):2616-28. doi: 10.1172/JCI64503. Epub 2013 May 1. PubMed |
| A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. Kurokawa M, Kim J, Geradts J, Matsuura K, Liu L, Ran X, Xia W, Ribar TJ, Henao R, Dewhirst MW, Kim WJ, Lucas JE, Wang S, Spector NL, Kornbluth S. Sci Signal. 2013 May 7;6(274):ra32. doi: 10.1126/scisignal.2003741. PubMed |
| Rapid assessment of RNAi-mediated protein depletion by selected reaction monitoring mass spectrometry. Glukhova VA, Tomazela DM, Findlay GD, Monnat RJ Jr, MacCoss MJ. J Proteome Res. 2013 Jul 5;12(7):3246-54. doi: 10.1021/pr400067k. Epub 2013 Jun 10. PubMed |
| The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Evangelou K, Bartkova J, Kotsinas A, Pateras IS, Liontos M, Velimezi G, Kosar M, Liloglou T, Trougakos IP, Dyrskjot L, Andersen CL, Papaioannou M, Drosos Y, Papafotiou G, Hodny Z, Sosa-Pineda B, Wu XR, Klinakis A, Orntoft T, Lukas J, Bartek J, Gorgoulis VG. Cell Death Differ. 2013 Nov;20(11):1485-97. doi: 10.1038/cdd.2013.76. Epub 2013 Jul 12. PubMed |
| Genome-wide profiling reveals stimulus-specific functions of p53 during differentiation and DNA damage of human embryonic stem cells. Akdemir KC, Jain AK, Allton K, Aronow B, Xu X, Cooney AJ, Li W, Barton MC. Nucleic Acids Res. 2014 Jan;42(1):205-23. doi: 10.1093/nar/gkt866. Epub 2013 Sep 27. PubMed |
| Oncogene-like induction of cellular invasion from centrosome amplification. Godinho SA, Picone R, Burute M, Dagher R, Su Y, Leung CT, Polyak K, Brugge JS, Thery M, Pellman D. Nature. 2014 Jun 5;510(7503):167-71. doi: 10.1038/nature13277. Epub 2014 Apr 13. PubMed |
| MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism. Akita H, Marquardt JU, Durkin ME, Kitade M, Seo D, Conner EA, Andersen JB, Factor VM, Thorgeirsson SS. Cancer Res. 2014 Oct 15;74(20):5903-13. doi: 10.1158/0008-5472.CAN-14-0527. Epub 2014 Sep 4. PubMed |
| Beclin-1-p53 interaction is crucial for cell fate determination in embryonal carcinoma cells. Tripathi R, Ash D, Shaha C. J Cell Mol Med. 2014 Nov;18(11):2275-86. doi: 10.1111/jcmm.12386. Epub 2014 Sep 11. PubMed |
| Oxidative pentose phosphate pathway inhibition is a key determinant of antimalarial induced cancer cell death. Salas E, Roy S, Marsh T, Rubin B, Debnath J. Oncogene. 2015 Oct 5. doi: 10.1038/onc.2015.348. PubMed |
| Establishing a murine xenograft-model for long-term analysis of factors inducing chromosomal instability in myelodysplastic syndrome: Pitfalls and successes. Salari A, Thomay K, Himmler K, Vajen B, Schienke A, Hagedorn M, Ebersold J, Kreipe HH, Kruger A, Schambach A, Schlegelberger B, Gohring G. Cancer Genet. 2016 Jun;209(6):258-66. doi: 10.1016/j.cancergen.2016.04.004. Epub 2016 Apr 22. PubMed |
| NF-Y loss triggers p53 stabilization and apoptosis in HPV18-positive cells by affecting E6 transcription. Benatti P, Basile V, Dolfini D, Belluti S, Tomei M, Imbriano C. Oncotarget. 2016 Jul 19;7(29):45901-45915. doi: 10.18632/oncotarget.9974. PubMed |
| 53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration. Meitinger F, Anzola JV, Kaulich M, Richardson A, Stender JD, Benner C, Glass CK, Dowdy SF, Desai A, Shiau AK, Oegema K. J Cell Biol. 2016 Jul 18;214(2):155-66. doi: 10.1083/jcb.201604081. PubMed |
| Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Gollner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stolzel F, Herold S, Ehninger G, Kohler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Muller LP, Thiede C, Muller-Tidow C. Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12. PubMed |
| OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCdelta/p53. Omar HA, Tolba MF, Hung JH, Al-Tel TH. Front Pharmacol. 2016 Nov 30;7:463. eCollection 2016. PubMed |
| Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids. Unno K, Roh M, Yoo YA, Al-Shraideh Y, Wang L, Nonn L, Abdulkadir SA. Oncotarget. 2017 Apr 19. doi: 10.18632/oncotarget.17230. PubMed |
| Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids. Unno K, Roh M, Yoo YA, Al-Shraideh Y, Wang L, Nonn L, Abdulkadir SA. Oncotarget. 2017 Apr 19;8(31):51264-51276. doi: 10.18632/oncotarget.17230. eCollection 2017 Aug 1. PubMed |
| Senescence-associated reprogramming promotes cancer stemness. Milanovic M, Fan DNY, Belenki D, Dabritz JHM, Zhao Z, Yu Y, Dorr JR, Dimitrova L, Lenze D, Monteiro Barbosa IA, Mendoza-Parra MA, Kanashova T, Metzner M, Pardon K, Reimann M, Trumpp A, Dorken B, Zuber J, Gronemeyer H, Hummel M, Dittmar G, Lee S, Schmitt CA. Nature. 2018 Jan 4;553(7686):96-100. doi: 10.1038/nature25167. Epub 2017 Dec 20. PubMed |
| Overexpression of parkin rescues the defective mitochondrial phenotype and the increased apoptosis of Cockayne Syndrome A cells. Pascucci B, D'Errico M, Romagnoli A, De Nuccio C, Savino M, Pietraforte D, Lanzafame M, Calcagnile AS, Fortini P, Baccarini S, Orioli D, Degan P, Visentin S, Stefanini M, Isidoro C, Fimia GM, Dogliotti E. Oncotarget. 2016 Jun 7;8(61):102852-102867. doi: 10.18632/oncotarget.9913. eCollection 2017 Nov 28. PubMed |
| Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice. Karlin J, Allen J, Ahmad SF, Hughes G, Sheridan V, Odedra R, Farrington P, Cadogan EB, Riches LC, Garcia-Trinidad A, Thomason AG, Patel B, Vincent J, Lau A, Pike KG, Hunt TA, Sule A, Valerie NCK, Biddlestone-Thorpe L, Kahn J, Beckta JM, Mukhopadhyay N, Barlaam B, Degorce SL, Kettle J, Colclough N, Wilson J, Smith A, Barrett IP, Zheng L, Zhang T, Wang Y, Chen K, Pass M, Durant ST, Valerie K. Mol Cancer Ther. 2018 Aug;17(8):1637-1647. doi: 10.1158/1535-7163.MCT-17-0975. Epub 2018 May 16. PubMed |
| Acute telomere deprotection prevents ongoing BFB cycles and rampant instability in p16(INK4a)-deficient epithelial cells. Bernal A, Molto-Abad M, Dominguez D, Tusell L. Oncotarget. 2018 Jun 5;9(43):27151-27170. doi: 10.18632/oncotarget.25502. eCollection 2018 Jun 5. PubMed |
| Generation of Immortalised But Unstable Cells after hTERT Introduction in Telomere-Compromised and p53-Deficient vHMECs. Bernal A, Zafon E, Dominguez D, Bertran E, Tusell L. Int J Mol Sci. 2018 Jul 17;19(7). pii: ijms19072078. doi: 10.3390/ijms19072078. PubMed |
| Effect of TP53 contact and conformational mutations on cell survival and erythropoiesis of human hematopoietic stem cells in a long term culture model. Salari A, Thomay K, Lentes J, Ebersold J, Hagedorn M, Skawran B, Davenport C, Schambach A, Schlegelberger B, Gohring G. Oncotarget. 2018 Jul 6;9(52):29869-29876. doi: 10.18632/oncotarget.25581. eCollection 2018 Jul 6. PubMed |
| p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT. Yang-Hartwich Y, Tedja R, Roberts CM, Goodner-Bingham J, Cardenas C, Gurea M, Sumi NJ, Alvero AB, Glackin CA, Mor G. Mol Cancer Res. 2019 Jan;17(1):153-164. doi: 10.1158/1541-7786.MCR-18-0238. Epub 2018 Aug 21. PubMed |
| Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Bakht MK, Derecichei I, Li Y, Ferraiuolo RM, Dunning M, Oh SW, Hussein A, Youn H, Stringer KF, Jeong CW, Cheon GJ, Kwak C, Kang KW, Lamb AD, Wang Y, Dong X, Porter LA. Endocr Relat Cancer. 2018 Nov 23;26(2):131-146. doi: 10.1530/ERC-18-0226. PubMed |
| LncRNA Meg3 protects endothelial function by regulating the DNA damage response. Shihabudeen Haider Ali MS, Cheng X, Moran M, Haemmig S, Naldrett MJ, Alvarez S, Feinberg MW, Sun X. Nucleic Acids Res. 2018 Nov 22. pii: 5198489. doi: 10.1093/nar/gky1190. PubMed |
| Assessment of different strategies for scalable production and proliferation of human myoblasts. Chua MJ, Yildirim ED, Tan JE, Chua YB, Low SC, Ding SLS, Li CW, Jiang Z, Teh BT, Yu K, Shyh-Chang N. Cell Prolif. 2019 May;52(3):e12602. doi: 10.1111/cpr.12602. Epub 2019 Mar 19. PubMed |
| Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Forte IM, Indovina P, Iannuzzi CA, Cirillo D, Di Marzo D, Barone D, Capone F, Pentimalli F, Giordano A. Int J Oncol. 2019 Jun;54(6):2189-2199. doi: 10.3892/ijo.2019.4788. Epub 2019 Apr 16. PubMed |
| The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells. Cai J, Xia J, Zou J, Wang Q, Ma Q, Sun R, Liao H, Xu L, Wang D, Guo X. FEBS Open Bio. 2020 Apr;10(4):535-545. doi: 10.1002/2211-5463.12806. Epub 2020 Mar 6. PubMed |
| Cell competition constitutes a barrier for interspecies chimerism. Zheng C, Hu Y, Sakurai M, Pinzon-Arteaga CA, Li J, Wei Y, Okamura D, Ravaux B, Barlow HR, Yu L, Sun HX, Chen EH, Gu Y, Wu J. Nature. 2021 Apr;592(7853):272-276. doi: 10.1038/s41586-021-03273-0. Epub 2021 Jan 28. PubMed |
| Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Ghosh M, Saha S, Bettke J, Nagar R, Parrales A, Iwakuma T, van der Velden AWM, Martinez LA. Cancer Cell. 2021 Apr 12;39(4):494-508.e5. doi: 10.1016/j.ccell.2021.01.003. Epub 2021 Feb 4. PubMed |
| Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p. Xia Y, Chen S, Cui J, Wang Y, Liu X, Shen Y, Gong L, Jiang X, Wang W, Zhu Y, Sun S, Li J, Zou Y, Shi B. Biochem Pharmacol. 2021 Jun;188:114575. doi: 10.1016/j.bcp.2021.114575. Epub 2021 Apr 20. PubMed |
| Estrogen Receptor-Alpha and p53 Status as Regulators of AMPK and mTOR in Luminal Breast Cancer. Gandhi N, Oturkar CC, Das GM. Cancers (Basel). 2021 Jul 19;13(14). pii: cancers13143612. doi: 10.3390/cancers13143612. PubMed |
| Small-Molecule MMRi62 Induces Ferroptosis and Inhibits Metastasis in Pancreatic Cancer via Degradation of Ferritin Heavy Chain and Mutant p53. Li J, Lama R, Galster SL, Inigo JR, Wu J, Chandra D, Chemler SR, Wang X. Mol Cancer Ther. 2022 Apr 1;21(4):535-545. doi: 10.1158/1535-7163.MCT-21-0728. PubMed |
| Modest increase of KIF11 expression exposes fragilities in the mitotic spindle, causing chromosomal instability. Dale KL, Armond JW, Hynds RE, Vladimirou E. J Cell Sci. 2022 Sep 1;135(17):jcs260031. doi: 10.1242/jcs.260031. Epub 2022 Aug 30. PubMed |
| Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status. Lama R, Xu C, Galster SL, Querol-Garcia J, Portwood S, Mavis CK, Ruiz FM, Martin D, Wu J, Giorgi MC, Bargonetti J, Wang ES, Hernandez-Ilizaliturri FJ, Koudelka GB, Chemler SR, Munoz IG, Wang X. Front Oncol. 2022 Aug 5;12:933446. doi: 10.3389/fonc.2022.933446. eCollection 2022. PubMed |
| Mutant p53 Depletion by Novel Inhibitors for HSP40/J-Domain Proteins Derived from the Natural Compound Plumbagin. Alalem M, Bhosale M, Ranjan A, Yamamoto S, Kaida A, Nishikawa S, Parrales A, Farooki S, Anant S, Padhye S, Iwakuma T. Cancers (Basel). 2022 Aug 29;14(17):4187. doi: 10.3390/cancers14174187. PubMed |
| p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression. Ghosh M, Saha S, Li J, Montrose DC, Martinez LA. Mol Cell. 2023 Jan 19;83(2):266-280.e6. doi: 10.1016/j.molcel.2022.12.023. Epub 2023 Jan 12. PubMed |
| Adult progenitor rejuvenation with embryonic factors. Wang P, Liu X, Chen Y, Jun-Hao ET, Yao Z, Min-Wen JC, Yan-Jiang BC, Ma S, Ma W, Luo L, Guo L, Song D, Shyh-Chang N. Cell Prolif. 2023 May;56(5):e13459. doi: 10.1111/cpr.13459. Epub 2023 May 12. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.